JP2015500827A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500827A5
JP2015500827A5 JP2014545387A JP2014545387A JP2015500827A5 JP 2015500827 A5 JP2015500827 A5 JP 2015500827A5 JP 2014545387 A JP2014545387 A JP 2014545387A JP 2014545387 A JP2014545387 A JP 2014545387A JP 2015500827 A5 JP2015500827 A5 JP 2015500827A5
Authority
JP
Japan
Prior art keywords
antigen
toxa
seq
toxb
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014545387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500827A (ja
JP6084631B2 (ja
Filing date
Publication date
Priority claimed from GB201121149A external-priority patent/GB201121149D0/en
Priority claimed from GBGB1217321.7A external-priority patent/GB201217321D0/en
Application filed filed Critical
Priority claimed from PCT/IB2012/002955 external-priority patent/WO2013084071A2/en
Publication of JP2015500827A publication Critical patent/JP2015500827A/ja
Publication of JP2015500827A5 publication Critical patent/JP2015500827A5/ja
Application granted granted Critical
Publication of JP6084631B2 publication Critical patent/JP6084631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014545387A 2011-12-08 2012-12-07 Clostridiumdifficile毒素ベースのワクチン Active JP6084631B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1121149.7 2011-12-08
GB201121149A GB201121149D0 (en) 2011-12-08 2011-12-08 Clostridium difficile toxin-based vaccine
GBGB1217321.7A GB201217321D0 (en) 2012-09-27 2012-09-27 Vaccine
GB1217321.7 2012-09-27
PCT/IB2012/002955 WO2013084071A2 (en) 2011-12-08 2012-12-07 Clostridium difficile toxin-based vaccine

Publications (3)

Publication Number Publication Date
JP2015500827A JP2015500827A (ja) 2015-01-08
JP2015500827A5 true JP2015500827A5 (https=) 2016-01-14
JP6084631B2 JP6084631B2 (ja) 2017-02-22

Family

ID=47747684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014545387A Active JP6084631B2 (ja) 2011-12-08 2012-12-07 Clostridiumdifficile毒素ベースのワクチン

Country Status (15)

Country Link
US (1) US9694063B2 (https=)
EP (1) EP2788022B1 (https=)
JP (1) JP6084631B2 (https=)
KR (1) KR20140101835A (https=)
CN (1) CN103974718A (https=)
AU (1) AU2012349753A1 (https=)
BR (1) BR112014013876A2 (https=)
CA (1) CA2858519A1 (https=)
ES (1) ES2704069T3 (https=)
IL (1) IL232957A0 (https=)
IN (1) IN2014CN04071A (https=)
MX (1) MX2014006630A (https=)
RU (1) RU2014127714A (https=)
SG (1) SG11201402375VA (https=)
WO (1) WO2013084071A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
SG11201500980WA (en) * 2012-09-19 2015-04-29 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
ES2749701T3 (es) * 2014-06-25 2020-03-23 Glaxosmithkline Biologicals Sa Composición inmunógena de Clostridium difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
AU2022249381A1 (en) * 2021-04-02 2023-11-09 Matrivax, Inc. METHODS AND COMPOSITIONS FOR TREATING <i>CLOSTRIDIODES DIFFICILE</i> INFECTIONS

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2203504A1 (en) 1994-10-24 1996-05-02 James A. Williams Vaccine and antitoxin for treatment and prevention of c. difficile disease
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU720567B2 (en) 1995-07-07 2000-06-08 Oravax, Inc Clostridium difficile toxins as mucosal adjuvants
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP1105153A4 (en) 1996-08-28 2005-01-19 Ophidian Pharm Inc POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM)
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001085748A2 (en) * 2000-05-10 2001-11-15 Glycodesign Inc. Designing modulators for glycosyltransferases
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
US20040107461A1 (en) * 2001-03-30 2004-06-03 Padma Commuri Glucan chain length domains
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
LT2857418T (lt) 2004-02-06 2017-09-25 University Of Massachusetts Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
CN101500581B (zh) 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
EP2054044B1 (de) 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
CA2693958A1 (en) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
US8524444B2 (en) * 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
KR20120061053A (ko) * 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(iPS) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
AU2010325992A1 (en) * 2009-12-02 2012-05-31 Tufts University Atoxic recombinant holotoxins of Clostridium difficile as immunogens
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2553102B1 (en) 2010-03-30 2015-12-09 Pfenex Inc. High level expression of recombinant toxin proteins
KR101820987B1 (ko) * 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
US8431361B2 (en) 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
AR086199A1 (es) * 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
EP2714910B1 (en) 2011-05-27 2018-01-10 GlaxoSmithKline Biologicals SA Immunogenic composition
AR087716A1 (es) * 2011-08-31 2014-04-09 Valent Biosciences Corp Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Similar Documents

Publication Publication Date Title
JP2015500827A5 (https=)
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
RU2014117068A (ru) Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
JP2013523718A5 (https=)
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
JP2016504993A5 (https=)
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2012501959A5 (https=)
JP2018509935A5 (https=)
JP2015214545A5 (https=)
NZ612315A (en) Compositions for immunising against staphylococcus aureus
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
JP2015096557A5 (https=)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2014530010A5 (https=)
JP2015501656A5 (https=)
IL276210B2 (en) Mers-cov vaccine
JP2015529677A5 (https=)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
JP2013504556A5 (https=)